ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: preliminary results of first-in-human phase I study in Japan - Goto, Y; Nokihara, H; Murakami, H (ASCO Meet Abstr, 2015)
(Suppl): abstract 8014